Crossmark

CSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease

Crossref DOI link: https://doi.org/10.1186/s13195-019-0481-4

Published Online: 2019-03-28

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Boumenir, Adla

Cognat, Emmanuel

Sabia, Severine

Hourregue, Claire

Lilamand, Matthieu

Dugravot, Aline

Bouaziz-Amar, Elodie

Laplanche, Jean-Louis

Hugon, Jacques

Singh-Manoux, Archana

Paquet, Claire

Dumurgier, Julien https://orcid.org/0000-0003-2070-9706
License Information

Text and Data Mining valid from 2019-03-28
More Information

Article History

Received: 10 December 2018

Accepted: 8 March 2019

First Online: 28 March 2019

Ethics approval and consent to participate

: The study was approved by the Ethical Committee of Paris University Hospitals; all participants provided written informed consent.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.